12:00 AM
Aug 27, 2012
 |  BC Week In Review  |  Company News  |  Deals

Celgene, GlobeImmune deal

GlobeImmune extended the option period for Celgene to license pancreatic cancer product GI-4000, according to GlobeImmune's updated S-1 registration statement filed on Aug. 16. Celgene will now have until after GlobeImmune delivers data from the Phase II portion of a planned Phase...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >